Viraferonpeg 50mcg Injection

Aperçu du produit

About Viraferonpeg 50mcg Injection

Viraferonpeg 50mcg Injection is a prescription medicine containing pegylated interferon alpha 2B. It is formulated as a sterile solution for subcutaneous injection. The product is used under the supervision of a qualified healthcare professional. Each vial contains 50 micrograms of the active ingredient in a clear, colorless liquid. The medication is stored in a refrigerator at 2°C to 8°C and should be protected from light. Before use, the vial should be inspected for particulate matter or discoloration. The injection is administered using a pre‑filled syringe or a compatible needle set. Proper injection technique and site rotation are recommended to reduce discomfort and local reactions. The medication is intended for therapeutic use only and should not be shared with others. Patients should inform their healthcare provider of any medical conditions or medications they are taking before starting treatment. The product is manufactured in accordance with Good Manufacturing Practice (GMP) guidelines and is subject to regulatory approval in the regions where it is marketed.

Key Benefits & Uses

• Provides antiviral activity against a range of viral infections.
• Helps modulate the immune response to reduce viral replication.
• Can be used as part of a comprehensive treatment plan under medical supervision.

Active Ingredient & Action

The active ingredient, pegylated interferon alpha 2B, is a modified form of interferon alpha that has a polyethylene glycol (PEG) molecule attached. This modification increases the drug’s half‑life, allowing for less frequent dosing. Interferon alpha 2B works by binding to specific receptors on cell surfaces, triggering a cascade of antiviral and immunomodulatory effects. The pegylation process also reduces the frequency of injection and improves patient compliance. The medication’s mechanism of action involves inhibition of viral replication, enhancement of natural killer cell activity, and modulation of cytokine production.

Important Notes

Viraferonpeg 50mcg Injection should only be used under the guidance of a qualified healthcare professional. Patients should be monitored for potential side effects such as flu‑like symptoms, injection site reactions, and changes in blood counts. The medication is contraindicated in individuals with severe liver disease or uncontrolled thyroid disorders. Patients should avoid alcohol consumption during treatment. Pregnant or breastfeeding women should consult their healthcare provider before using this product. The medication should be kept out of reach of children and pets. If a dose is missed, patients should contact their healthcare provider for guidance on how to proceed. Proper disposal of used syringes and needles is essential to prevent accidental injury or contamination.